Company news

Nyrada, Inc. news in 2026

Nyrada, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Quotation of Attaching Options

November 4, 2026

Quotation of Attaching Options

November 4, 2026

Update - Proposed issue of securities - NYR

November 4, 2026

Update - Proposed issue of securities - NYR

November 4, 2026

Quotation of New Options

November 2, 2026

Notice of Initial Substantial Holding - J Moore

November 1, 2026

Update - Proposed issue of securities - NYR

November 1, 2026

Change of Director's Interest Notice - JM

November 1, 2026

Application for quotation of securities - NYR

October 29, 2026

Application for quotation of securities - NYR

October 29, 2026

PROTECT-MI Phase IIa Clinical Trial Update No 4

October 29, 2026

Securities Purchase Plan Results

October 27, 2026

Quarterly Activities Report and Appendix 4C

October 18, 2026

Quarterly Activities Report and Appendix 4C

October 18, 2026

PROTECT-MI Phase IIa Clinical Trial Update No 3

October 15, 2026

Nyrada Receives Positive FDA Feedback

October 12, 2026

Attaching Options Prospectus

October 11, 2026

Securities Purchase Plan Offer Booklet

October 11, 2026

2026 AGM Letter to Shareholders, Notice of Meeting & Proxy

October 7, 2026

Nyrada US Patent for Xolatryp Granted

September 30, 2026

Cleansing Statement

September 24, 2026

Application for quotation of securities - NYR

September 24, 2026

Proposed issue of securities - NYR

September 20, 2026

Proposed issue of securities - NYR

September 20, 2026

Proposed issue of securities - NYR

September 20, 2026

Proposed issue of securities - NYR

September 20, 2026

Cap Raise Deck-Building the Future of TRPC-based Therapies

September 20, 2026

Nyrada Successfully Raises AU$12.0 Million Via Placement

September 20, 2026

Trading Halt

September 16, 2026

Investor Presentation- Evans&Partners Small Cap Healthcare

September 15, 2026

Change in substantial holding - M Azzi

August 27, 2026

Cleansing Statement

August 24, 2026

Application for quotation of securities - NYR

August 24, 2026

Xolatryp Demonstrates Cardioprotection in Preclinical Study

August 20, 2026

Nyrada Full Year Results FY2026

August 17, 2026

Annual Report for year ended 30 June 2026

August 17, 2026

Preliminary Final Report

August 17, 2026

Appendix 4G and Corporate Governance Statement

August 17, 2026

Change in substantial holding - M Azzi

August 4, 2026

CSANZ26 Conference Poster

August 4, 2026

Decks in 2026